Symbols

TRVI

Trevi Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 0

Consensus Rating "Buy"

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TRVI

Trevi Therapeutics, Inc.

A clinical-stage biopharmaceutical company that develops treatments for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis

Industry

Pharmaceutical

Established Date

03/17/2011

Listing Date

05/07/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.trevitherapeutics.com

Security Type

Common stock

Office address

195 Church Street, 16th Floor, New Haven, Connecticut 06510

Business

Introduction

Trevi Therapeutics, Inc., was incorporated under the laws of the State of Delaware on March 17, 2011. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing nalbuphine ER for the treatment of serious neuro-mediated diseases. The company is currently developing nalbuphine ER for the treatment of chronic itching, chronic cough, and levodopa-induced dyskinesia, or LID, in patients with idiopathic pulmonary fibrosis, or IPF. These conditions share a common pathophysiology, which is mediated by opioid receptors in the central and peripheral nervous systems. Due to the mechanism of action of nalbuphine as an opioid receptor modulator, the company believes it has the potential to effectively treat these diseases.

Earnings Call

Q1/2025

Estimate EPS-0.12

Actual EPS-0.09

Estimate Revenue--

Actual Revenue0

Trevi Therapeutics Q1 2025: Unraveling Contradictions in Clinical Trial Timelines and Study Impacts

May 19,2025 09:19·
Earnings Decrypt

Company Financials

EPS

TRVI has released its 2025 Q3 earnings. EPS was reported at -0.08, versus the expected -0.1, beating expectations. The chart below visualizes how TRVI has performed over recent quarters, highlighting trends in earnings surprises.